Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.

Front Immunol · 2025 · PMC12267214 · PMID 40677703

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

showed a trendp = 0.079so close (0.05 < p ≤ 0.1)

The trial showed a trend toward improved median PFS with T + E (3.8 months vs. 1.9 months, HR 0.64, p = 0.079).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.